<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790893</url>
  </required_header>
  <id_info>
    <org_study_id>IND 117497</org_study_id>
    <nct_id>NCT01790893</nct_id>
  </id_info>
  <brief_title>Treatment for Presumed Ocular Histoplasmosis</brief_title>
  <acronym>HANDLE</acronym>
  <official_title>Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Kitchens, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Associates of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor safety outcomes for patients being treated with
      intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed
      Ocular Histoplasmosis Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular and systemic adverse events</measure>
    <time_frame>through Month 12</time_frame>
    <description>The primary objective of the study is the incidence and severity of ocular and systemic adverse events through Month 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Months 3, 6, 9 and 12</time_frame>
    <description>Mean change in BCVA from Baseline
Proportion of subjects gaining &gt;5,10 and 15 letters
Proportion of subjects losing &gt;5, 10 and 15 letters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>OCT changes</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>Mean change from baseline in central subfield thickness over time up to 12 months assessed on OCT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ocular Histoplasmosis</condition>
  <arm_group>
    <arm_group_label>intravitreal aflibercept injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <arm_group_label>intravitreal aflibercept injection</arm_group_label>
    <arm_group_label>intravitreal aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis
             demonstrated by active leakage on fluorescein angiography with spectal domain OCT
             evidence of subretinal or intraretinal fluid or PED.

          -  Active CNV may also be defined as demonstrating active subretinal hemorrhage.

          -  ETDRS Best corrected visual acuity 20/20-20/320.

          -  willing and able to comply with all study clinic visits and study related procedures.

          -  Willing to use and practice more than one form of contraceptives during the 13 month
             study for male and female.

          -  Provide signed informed consent

          -  Able to understand and complete study related questionnaires

        Exclusion Criteria:

          -  Under 18 years of age

          -  CNV due to other causes than Presumed Ocular Histoplasmosis

          -  Previous treatment in the study eye within 6 months prior to Day 1

          -  More than 5 Intravitreal injections of anti-VEGF therapy within previous 12 months

          -  Any clinical evidence of any other ocular condition other than Ocular histoplasmosis

          -  History of allergy to fluorescein

          -  Pregnant( or planning on becoming pregnant within the next 13 months) or breast
             feeding women

          -  Sexually Active Men or Women who are NOT willing to practice more than one form of
             contraceptives during the next 13 months.

          -  Anticipated or previous (within previous 3 months) systemic anti-VEGF therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Kitchens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Holcomb, COA</last_name>
    <phone>859-264-2905</phone>
    <email>dholcomb@retinaky.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southeast Retina</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Gardner</last_name>
      <phone>706-650-0061</phone>
      <email>jgardner@southeastretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Courtney Caulder</last_name>
      <phone>706-650-0061</phone>
      <email>ccaulder@southeastretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harinderjit Singh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Holcomb</last_name>
      <phone>859-264-2905</phone>
      <email>dholcomb@retinaky.com</email>
    </contact>
    <investigator>
      <last_name>John W. Kitchens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William J Wood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Stone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rick Isernhagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Moshfeghi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kingdon</last_name>
      <phone>513-569-3669</phone>
    </contact>
    <investigator>
      <last_name>Daniel Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Petersen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sisk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Foster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Riemann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Toussaint, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.retinaky.com</url>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Retina Associates of Kentucky</investigator_affiliation>
    <investigator_full_name>John Kitchens, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

